Sponsor Directory

Novartis Pharmaceuticals clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1758

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 20 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Interventions: [68Ga]Ga-NNS309, [177Lu]Lu-NNS309; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more

Conditions: Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: TIN816 70 mg lyophilisate powder, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more

Conditions: Sickle Cell Disease
Interventions: OTQ923; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Memphis, Tennessee

Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: PIT565; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Miami, Florida • Chicago, Illinois • Fairway, Kansas + 2 more

Conditions: Metastatic Uveal Melanoma
Interventions: DYP688; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Advanced Solid Tumors
Interventions: PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Houston, Texas

Conditions: Glioblastoma
Interventions: BKM120, Surgery; Drug · Procedure
Lead sponsor: L. Nicolas Gonzalez Castro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more

Conditions: Solid Tumor
Interventions: 68Ga-FAP-2286, 177Lu-FAP-2286; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 16 more

Conditions: Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions: LTP, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 16 more

About this Novartis Pharmaceuticals sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Novartis Pharmaceuticals is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Novartis Pharmaceuticals trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Novartis Pharmaceuticals clinical trials

Filter and sort this sponsor

Live official records

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

About this Novartis Pharmaceuticals sponsor directory page